MAPK p38 regulates inflammatory gene expression via tristetraprolin::Doing good by stealth by O'Neil, J D et al.
 
 
MAPK p38 regulates inflammatory gene expression
via tristetraprolin:
O'Neil, John; Ammit, A. J.; Clark, Ana
DOI:
10.1016/j.biocel.2017.11.003
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
O'Neil, JD, Ammit, AJ & Clark, AR 2018, 'MAPK p38 regulates inflammatory gene expression via tristetraprolin:
Doing good by stealth', The International Journal of Biochemistry & Cell Biology, vol. 94, pp. 6-9.
https://doi.org/10.1016/j.biocel.2017.11.003
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Contents lists available at ScienceDirect
International Journal of Biochemistry
and Cell Biology
journal homepage: www.elsevier.com/locate/biocel
Signalling networks in focus
MAPK p38 regulates inﬂammatory gene expression via tristetraprolin: Doing
good by stealth
J.D. O’Neila, A.J. Ammitb,c, A.R. Clarka,⁎
a Institute of Inﬂammation and Ageing, University of Birmingham, Birmingham B15 2WB, United Kingdom
bWoolcock Emphysema Centre, Woolcock Institute of Medical Research, University of Sydney, New South Wales, Australia
c School of Life Sciences, Faculty of Science, University of Technology, Sydney, New South Wales, Australia
A R T I C L E I N F O
Keywords:
MAPK p38
Tristetraprolin
Post-transcriptional regulation
Inﬂammation
Adenosine/uridine-rich element
A B S T R A C T
Tristetraprolin (TTP) is an RNA-destabilizing protein that exerts profound anti-inﬂammatory eﬀects by in-
hibiting the expression of tumour necrosis factor and many other inﬂammatory mediators. The mitogen-acti-
vated protein kinase (MAPK) p38 signaling pathway controls the strength and duration of inﬂammatory re-
sponses by regulating both the expression and function of TTP. The kinase MK2 (MAPK activated kinase 2) is
activated by MAPK p38, and in turn phosphorylates TTP at two critical serine residues. One consequence of these
phosphorylations is the protection of TTP from proteasome-mediated degradation. Another consequence is the
loss of mRNA destabilizing activity. The control of TTP expression and function by the MAPK p38 pathway
provides an elegant mechanism for coupling the on and oﬀ phases of inﬂammatory responses, and dictating the
precise kinetics of expression of individual inﬂammatory mediators.
1. Introduction
The mitogen-activated protein kinase (MAPK) p38 signaling
pathway and the ﬁrst generation of selective MAPK p38 inhibitors were
both discovered in the mid 1990s (Arthur and Ley, 2013). Mammalian
genomes encode four distinct MAPK p38 isoforms known as α, β, γ and
δ. MAPK p38α and β are commonly activated by stressful or pro-in-
ﬂammatory stimuli, and selectively inhibited by the drugs ﬁrst identi-
ﬁed at SmithKline Beecham. These compounds and selective inhibitors
generated by other pharmaceutical companies reduced the expression
of many inﬂammatory mediators, exerted therapeutic eﬀects in several
experimental models of inﬂammatory pathology, and ultimately un-
derwent clinical trials in various chronic inﬂammatory diseases. Al-
though few of these trials were reported in full, the outcomes appear to
have been uniformly and surprisingly negative, leading one commen-
tator to conclude that “The era of optimism surrounding the use of
MAPK p38 inhibition … is over” (Genovese, 2009). It remains open to
question whether the MAPK p38 pathway could still be therapeutically
targeted in inﬂammatory disease, for example by attacking diﬀerent
points in the signaling cascade, by inhibiting MAPK p38 itself in a
diﬀerent manner, or by selecting diﬀerent inﬂammatory pathologies for
treatment. Judgement of this issue requires a more complete under-
standing of how MAPK p38 regulates expression of inﬂammatory
mediators, and why such promising pre-clinical data failed to translate
into clinical eﬃcacy.
2. Post-transcriptional regulation of inﬂammatory responses
Although it is scarcely mentioned in some reviews, MAPK p38
regulates inﬂammatory responses largely at a post-transcriptional level.
Post-transcriptional regulation in the innate immune system has been
reviewed extensively (Carpenter et al., 2014; Tiedje et al., 2014). Many
of the factors induced by infection or injury have powerful, pleiotropic
eﬀects and can cause severe damage if their expression is unchecked.
Therefore rapid on-and-oﬀ switching of gene expression is fundamental
to the innate immune system. This type of regulation requires rapid
mRNA turnover, otherwise dynamic changes of transcription rate will
be negated by the long-lasting intermediates. Hence short half-lives are
highly characteristic of many inﬂammatory mediator mRNAs. In the
majority of cases deadenylation (the removal of the protective 3′ poly-
(A) tail) is the rate limiting step in mRNA degradation. Deadenylation is
regulated by sequences located within mRNA 3′ untranslated regions
(UTRs), which act as cognate sites for sequence-speciﬁc RNA binding
proteins. The best characterized of these regulatory sites are the ade-
nosine/uridine-rich elements (AREs), which are common in the 3′ UTRs
of inﬂammatory mRNAs, and often contain overlapping repeats of the
motif AUUUA. Unsurprisingly, rates of mRNA degradation can be
modulated in response to extracellular stimuli, providing additional
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mechanisms for the regulation of inﬂammatory responses. The phy-
siological importance of post-transcriptional mechanisms to in-
ﬂammatory and other immune responses has been illustrated by both
genome-wide and gene-targeted approaches (Brooks and Blackshear,
2013; Kontoyiannis et al., 1999; Rabani et al., 2014; Ross et al., 2015).
3. Tristetraprolin as a mediator of post-transcriptional regulation
by MAPK p38
Sustained MAPK p38 signaling is required for stabilization of many
pro-inﬂammatory mRNAs in several diﬀerent cell types (references in
Tiedje et al., 2014). AREs in the 3′ UTRs of these transcripts are ne-
cessary and suﬃcient for post-transcriptional regulation by MAPK p38
(Dean et al., 2003; Kontoyiannis et al., 1999; Marchese et al., 2010;
Tiedje et al., 2014; Tudor et al., 2009). Diﬀerent experimental ap-
proaches indicated that the eﬀects of MAPK p38 are mediated by the
downstream kinase MK2 (MAPK-activated kinase 2) (Tiedje et al.,
2014). Finally, MAPK p38 delayed the decay of target mRNAs by in-
hibiting their deadenylation (Dean et al., 2003). These observations led
to the hypothesis that an ARE-binding protein promotes the dead-
enylation and subsequent degradation of target mRNAs, and this pro-
tein can be inactivated by MK2 to promote mRNA stabilization.
The clearest and most consistent evidence points to tristetraprolin
(TTP) as a mediator of post-transcriptional eﬀects of the MAPK p38
pathway (Clark and Dean, 2016). Other putative mediators are dis-
cussed elsewhere (Tiedje et al., 2014). TTP, the product of the Zfp36
gene in mouse and the ZFP36 gene in man, is a principally cytoplasmic
protein of approximately 36 kD, and interacts with RNA via a central
domain containing two C3H-type zinc ﬁngers (ie. zinc is coordinated by
three cysteine and one histidine residues) (Brooks and Blackshear,
2013). Its consensus core binding motif, UAUUUAU, is found in the 3′
UTRs of MAPK p38-sensitive mRNAs. The Zfp36 knockout mouse has a
severe, spontaneous inﬂammatory phenotype in which the dominant
pathological features are driven by increased stability of tumour ne-
crosis factor (Tnf) mRNA and dysregulated expression of TNF protein.
However, growing numbers of genes are also found to be post-tran-
scriptionally dysregulated in Zfp36-/- cells, contributing to diﬀerent
aspects of the phenotype (Brooks and Blackshear, 2013). This reﬂects
the fact that TTP binds to hundreds of mRNA targets, many of which are
involved in cellular responses to stressful and pro-inﬂammatory stimuli
(Sedlyarov et al., 2016; Tiedje et al., 2016). Once bound to target
transcripts, TTP promotes their degradation by recruiting various nu-
cleolytic protein complexes (Fig. 1). Amongst these, the most important
is likely to be the CCR4-NOT (carbon catabolite repression 4− negative
on TATA-less) complex, which mediates mRNA deadenylation. Im-
portantly, MAPK p38 inhibitors failed to destabilize several
inﬂammatory mRNAs or to inhibit the expression of the corresponding
proteins in Zfp36-/- macrophages (Carballo et al., 2001; Tudor et al.,
2009).
4. Mechanisms of regulation of TTP by the MAPK p38 pathway
TTP is expressed at very low levels in resting macrophages, and as it
is synthesized in response to LPS (lipopolysaccharide) it becomes ex-
tensively phosphorylated (Mahtani et al., 2001). More than 30 sites of
phosphorylation of TTP have been documented, but only a few studied
in detail (Clark and Dean, 2016). In vitro TTP is eﬃciently phos-
phorylated by MK2 at serines 52, 178 and 316 (mouse coordinates)
(Chrestensen et al., 2004; Mahtani et al., 2001; Stoecklin et al., 2004).
The phosphorylation of S52 and S178 promotes binding of 14-3-3
proteins, abundant low molecular-weight adaptors that speciﬁcally re-
cognize phosphorylated client proteins and help to bring about phos-
phorylation-mediated changes of localization and function. As a con-
sequence of these phosphorylations, the recruitment of the CCR4-NOT
complex is impaired, the localization of TTP to cytoplasmic sites of
mRNA turnover is altered, and target mRNAs are stabilized (Clement
et al., 2011; Marchese et al., 2010; Stoecklin et al., 2004). S316 lies
within a highly conserved C-terminal CCR4-NOT recruitment domain.
Its phosphorylation is also thought to impair recruitment of the dead-
enylase complex, although likely by a diﬀerent mechanism (Fabian
et al., 2013).
TTP lacks deﬁned structure outside its central zinc ﬁnger domain,
and is targeted for degradation by the proteasome via an unfolded
protein response (Ngoc et al., 2014). Phosphorylation of S52 and S178
prevents TTP protein degradation (Brook et al., 2006; Hitti et al., 2006;
Ngoc et al., 2014), possibly via imposition of stable structure. Depho-
sphorylation and activation of TTP can be carried out by protein
phosphatase 2A (PP2A), but this is accompanied by a decrease in TTP
protein stability (Brook et al., 2006; Frasca et al., 2010; Mahtani et al.,
2001; Rahman et al., 2016; Sun et al., 2007). As outlined in Fig. 2, the
dynamic equilibrium between phosphorylated (inactive) and unpho-
sphorylated (active) TTP is believed to contribute to the precise tem-
poral orchestration of inﬂammatory gene expression by the MAPK p38
pathway (Clark and Dean, 2016; Kratochvill et al., 2011; Prabhala
et al., 2015; Rabani et al., 2014; Sedlyarov et al., 2016). The coupling
between TTP protein stability and mRNA destabilizing activity may also
help to explain the loss of eﬃcacy of MAPK p38 inhibitors in clinical
trials, as explored in more detail elsewhere (Clark and Dean, 2016).
Another interesting consequence is that the quantity of TTP protein in a
cell or tissue may be inversely related to its mRNA destabilizing ac-
tivity. This could explain the abundance of TTP found at sites of in-
ﬂammation such as the rheumatoid synovium, where it is co-localized
with active MAPK p38 (Ross et al., 2017).
5. A TTP knock-in mouse with an inﬂammation-resistant
phenotype
To test the working model described above, we generated a knock-
in mouse strain, in which serines 52 and 178 of endogenous TTP protein
were substituted by non-phosphorylatable alanine residues (Ross et al.,
2015). As predicted, TTP was expressed at very low levels in genetically
modiﬁed (Zfp36aa/aa) primary macrophages, to the extent that it was
almost undetectable in some experiments. However, it functioned very
eﬃciently as an mRNA destabilizing factor, and strongly inhibited the
expression of many inﬂammatory mediators (McGuire et al., 2016;
O'Neil et al., 2017; Ross et al., 2015; Tang et al., 2017). In vivo the
targeted mutagenesis of the Zfp36 gene conferred strong protection in
an experimental model of endotoxemia (Ross et al., 2015) and complete
protection in an experimental model of rheumatoid arthritis (Ross et al.,
2017). The hypo-inﬂammatory phenotype of Zfp36aa/aa mice was ac-
companied by striking decreases in the expression of many in-
ﬂammatory mediators in vivo, for example an almost 200-fold lower
Fig. 1. TTP interacts with multiple mRNA-processing factors. TTP interacts in a sequence-
speciﬁc manner with an adenosine/uridine-rich element (ARE) in the 3′ untranslated
region (UTR) of a target mRNA. A typical ARE sequence is shown below the schematic.
TTP can then interact with the CCR4/NOT complex to promote shortening of the poly-(A)
tail; with the exosome (Exo) to promote degradation of the mRNA body in the 3′ to 5′
direction; with the decapping complex (Dcp) to promote removal of the protective 7-
methylguanosine cap at the 5′ end of the mRNA; with exoribonuclease 1 (Xrn) to promote
degradation of the mRNA body in the 5′ to 3′ direction. ORF, open reading frame.
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serum level of IL-6 after injection of LPS (O'Neil et al., 2017; Ross et al.,
2015). Nevertheless, the strong evolutionary conservation of the sites of
MK2-mediated phosphorylation (Clark and Dean, 2016) implies that
loss of MAPK p38-mediated control of TTP function confers a selective
disadvantage. So far we have discovered only subtle alterations of
adaptive immunity in Zfp36aa/aa mice (Ross et al., 2015), and no
serious harmful consequences of the targeted mutation (O'Neil et al.,
2017). In summary, the mutant form of TTP exerts profound anti-in-
ﬂammatory eﬀects despite its near undetectable levels of expression, a
phenomenon we describe as, “Doing good by stealth”.
6. Dual speciﬁcity phosphatase 1 controls TTP function
Dual speciﬁcity phosphatase 1 (DUSP1) dephosphorylates and in-
activates MAPK p38. Its expression is induced by pro-inﬂammatory
stimuli, constituting a negative feedback loop to limit the duration of
MAPK p38 signaling. Defective negative feedback control causes ex-
cessive inﬂammatory responses in Dusp1-/-mice and cells. The Dusp1-/-
phenotype is largely explained by increased phosphorylation and in-
activation of TTP, and consequent stabilization of TTP target transcripts
(Smallie et al., 2015). The cross-talk between DUSP1 and TTP controls
the expression of several important inﬂammatory mediators including
TNF, IL-6 (interleukin 6), IL-1β, CXCL1 (chemokine CXC motif ligand
1), CXCL2, Cyclooxygenase 2 and Interferon β (McGuire et al., 2016;
O'Neil et al., 2017; Smallie et al., 2015; Tang et al., 2017). An im-
plication is that agonists which enhance or prolong the expression of
DUSP1 could reduce expression of these genes and exert anti-in-
ﬂammatory eﬀects by modulating the equilibrium between phos-
phorylated and unphosphorylated TTP. Prostaglandin E2 (PGE2) exerts
anti-inﬂammatory eﬀects in this way (Rumzhum and Ammit, 2016).
Whilst Dusp1-/- macrophages over-express TNF and Zfp36aa/aa mac-
rophages under-express TNF, both are similarly insensitive to the anti-
inﬂammatory eﬀects of PGE2 (Tang et al., 2017). Other agonists that
elevate intracellular cAMP and enhance DUSP1 expression may exert
anti-inﬂammatory eﬀects via the same mechanism. Glucocorticoids are
well known to increase the expression of DUSP1, and their anti-in-
ﬂammatory eﬀects are also partly mediated by modulation of TTP
function (Prabhala et al., 2016).
7. The critical role of PP2A
The dephosphorylation and activation of phosphorylated TTP is
mediated by PP2A (Sun et al., 2007). Both under resting conditions and
after stimulation of cells with TNF, PP2A restrains the expression of
inﬂammatory genes, at least in part by controlling TTP function
(Rahman et al., 2016; Rahman et al., 2015). It follows that targeted
stimulation of PP2A should exert anti-inﬂammatory eﬀects by enhan-
cing TTP function. This prediction has been tested and proven correct
both in vitro and in vivo, using chemically distinct PP2A-activating
molecules (Rahman et al., 2016; Ross et al., 2017). In primary macro-
phages, anti-inﬂammatory eﬀects of one PP2A agonist were dependent
on the presence of intact phosphorylation sites S52 and S178, and an
intact TTP binding site in the target mRNA (Ross et al., 2017). We
conclude that PP2A agonists may have therapeutic utility in chronic
inﬂammatory diseases, where aberrant activation of the MAPK p38
pathway leads to the accumulation of TTP in a phosphorylated and
inactive form.
8. Conclusion
The intimate link between MAPK p38 and TTP provides an elegant
system for ﬁne-tuning inﬂammatory responses, in terms of both the
strength of response to challenge and the precise timing of on- and oﬀ-
switches. The physiological signiﬁcance of this mechanism is well il-
lustrated by the dramatic inﬂammation-resistant phenotype arising
from substitution of just two amino acids of endogenous TTP (McGuire
et al., 2016; O'Neil et al., 2017; Ross et al., 2017; Ross et al., 2015;
Smallie et al., 2015; Tang et al., 2017). At least in principle, this me-
chanism of control of inﬂammatory responses appears to be tractable as
a novel therapeutic target (Rahman et al., 2016; Ross et al., 2017).
We lack space for discussion of other interesting matters such as the
relationship between the MAPK p38 dependent phosphorylations and
other phosphorylations of TTP (Clark and Dean, 2016), or the re-
lationship between the turnover of TTP protein and that of its mRNA
targets (Brooks, 2010). Phosphorylation of TTP clearly inﬂuences
translation as well as stability of target mRNAs, which is neglected here
but discussed elsewhere (Tiedje et al., 2014; Clark and Dean, 2016).
Fig. 2. Phosphorylation-regulated function of TTP
during the evolution of an inﬂammatory response.
Tnf is used as an exemplar TTP-regulated transcript
here. 1. In the resting state TTP is expressed at very
low levels. Any TTP present is likely to be pre-
dominantly unphosphorylated at S52 and S178, and
may be restricted to the nucleus (Brook et al., 2006).
Nuclear functions of TTP are not clear. One possibi-
lity is that nuclear TTP may help to prevent leaky
expression of pro-inﬂammatory mediators such as
TNF, which often have constitutive RNA polymerase
2 recruitment at their promoters. 2. In respose to an
inﬂammatory challenge, expression of TTP is ac-
companied by its MK2-mediated phosphorylation at
S52 and S178. These phosphorylations render TTP
inactive, and target mRNAs are initially stable. 3. As
MAPK p38 activity declines, the pool of inactive TTP
is dephosphorylated by MK2 and becomes active.
Target mRNAs are consequently destabilized, driving
the oﬀ-phase of gene expression. The exact tipping
point between on- and oﬀ-phases depends on the
strength and duration of transcriptional activation
and (possibly) the aﬃnity of the particular mRNA for
TTP (McGuire et al., 2016; Tang et al., 2017). 4.
Ubiquitin-independent degradation of TTP protein
facilitates a return to ground state.
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The issue of timing is also too complex to do justice to here. For ex-
ample, sustained inhibition of MAPK p38 depletes cells of TTP protein
(Mahtani et al., 2001) and fails to destabilize target mRNAs (Tudor
et al., 2009), suggesting that the timing of p38-targeting drug delivery
should be explored in more detail. DUSP1-mediated negative feedback
results in oscillations of MAPK p38 activity, which are required for
eﬃcient expression of inﬂammatory mediators (Tomida et al., 2015). It
is not known whether oscillations of MAPK p38 activity inﬂuence TTP
activity. Finally, the timing of stimuli that enhance DUSP1 expression is
likely to be crucial (Tang et al., 2017). In vitro assays are poor at cap-
turing the complexities of asynchronous and conﬂicting cell stimula-
tions that exist in the real world. More sophisticated systems are re-
quired to explore the links between MAPK p38 and TTP in vivo.
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